IgG Fc receptor polymorphisms in human disease: Implications for intravenous immunoglobulin therapy

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 4, 2003, Pages 697-703

  Binstadt, Bryce A ^b   Geha, Raif S ^b   Bonilla, Francisco A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

Autoimmune; Fc receptor; Guillain Barr ; Intravenous immunoglobulin; ITP; Lupus; Multiple sclerosis; Polymorphism; Vasculitis

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN;

AUTOIMMUNE DISEASE; BINDING AFFINITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENETIC POLYMORPHISM; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0242600804     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.1380     Document Type: Review

References (72)

1. Van der Pol, W-L, van de Winkel JGJ. IgG receptor polymorphisms: risk factors for disease. Immunogenetics 1998;48:222-32.
2. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001;19:275-90.
3. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002;2:580-92.
4. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55.
5. Ott VL, Fong DC, Cambier JC. FcγRIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol 2001;108:S95-8.
6. Zhuang Q, Bisotto S, Fixman ED, Mazer B. Suppression of IL4- and CD40-induced B-lymphocyte activation by intravenous immunoglobulin is not mediated through the inhibitory IgG receptor FcγRIIb. J Allergy Clin Immunol 2002;110:480-3.
7. Lehrnbecher R, Foster CB, Zhu S, Leitman SF, Goldin LR, Huppi K, et al. Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations. Blood 1999;94:4220-32.
8. Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fcγ receptor IIA and Fcγ receptor IIB: independent mechanisms for differences in human phagocyte function. J Clin Invest 1992;81:1274-81.
9. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
10. Debre M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993;342:945-9.
11. Burdach SE, Evers KG, Geursen RG. Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: comparative efficacy of 7S and 5S preparations. J Pediatr 1986;109:770-5.
12. Jungi TW, Brcic M, Kuhnert P, Spycher MO, Li F, Nydegger UE. Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes. Clin Exp Immunol 1990;82:163-9.
13. Ericson SG, Coleman KD, Wardwell K, Baker S, Fanger MW, Guyre PM, et al. Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. Br J Haematol 1996;92:718-24.
14. Samuellson A, Towers T, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-6.
15. McKenzie SE, Taylor SM, Malladi P, Yuhan H, Cassel DL, Chien P, et al. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol 1999;162:4311-8.
16. Williams Y, Lynch S, McCann S, Smith O, Feighery C, Wehlan A. Correlation of platelet FcγRIIA polymorphism in refractory idiopathic (immune) thrombocytopenic purpura. Br J Haematol 1998;101:779-82.
17. Fujimoto T-T, Inoue M, Shimomura T, Fujimura K. Involvement of Fcγ receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura. Br J Haematol 2001;115:125-30.
18. Foster CB, Zhu S, Erichsen HC, Lehrnbecher T, Hart ES, Choi E, et al. Polymorphisms in inflammatory cytokine and Fcγ receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. Br J Haematol 2001;113:596-9.
19. Tijhuis GJ, Klaasen RJ, Modderman PW, Ouwehand WH, von dem Borne AE. Quantification of platelet-bound immunoglobulins of different class and subclass using radiolabelled monoclonal antibodies: assay conditions and clinical application. Br J Haematol 1991;77:93-101.
20. Kimberly RP, Salmon JE, Bussel JB, Crow MK, Hilgartner MW. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol 1984;132:745-50.
21. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001;98:1095-9.
22. Davies KA, Robson MG, Peters AM, Norsworthy P, Nash JT, Walport MJ. Defective Fc-dependent processing of immune complexes in patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:1028-38.
23. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998;279:1052-4.
24. Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, et al. FcγRIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996:97:1348-54.
25. Song YW, Han C-W, Kang S-W, Baek H-J, Lee E-B, Shin C-H, et al. Abnormal distribution of Fcγ receptor type IIA polymorphisms in Korean patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:421-6.
26. Manger K, Repp R, Spriewald BM, Rascu A, Geiger A, Wassmuth R, et al. Fcγ receptor IIA polymorphism in Caucasian patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1181-9.
27. Duits AJ, Bootsma H, Derksen RHWM, Spronk PE, Kater L, Kallenberg CGM, et al. Skewed distribution of IgG Fc receptor IIA (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 1995;39:1832-6.
28. Manger K, Repp R, Jansen M, Geisselbrecht M, Wassmuth R, Westerdaal NAC, et al. Fcγ receptor IIA, IIIA, and IIIB polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. Ann Rheum Dis 2002;61:786-92.
29. Dijstelbloem HM, Bijl M, Fijnheer R, Scheepers RH, Oost WW, Jansen MD, et al. Fc gamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Arthritis Rheum 2000;43:2793-800.
30. Botto M, Theodoridis E, Thompson EM, Beynon HLC, Briggs D, Isenberg DA, et al. FcγRIIA polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clin Exp Immunol 1996;104:264-8.
31. Koene HR, Kleijer M, Swaak AJG, Sullivan KE, Bijl M, Petri MA, et al. The FcγRIIIA-158F allele is a risk factor for systemic lupus erythematosus. Arthritis Rheum 1998;41:1813-8.
32. Hatta Y, Tsuchiya N, Ohashi J, Matsushita M, Fujiwara K, Hagiwara K, et al. Association of Fc gamma receptor IIIB, but not Fc gamma receptor IIA and IIIA polymorphisms with systemic lupus erythematosus in Japanese. Genes Immun 1999;1:53-60.
33. Oh M, Petri MA, Kim NH, Sullivan KE. Frequency of the FcγRIIIA-158F allele in African American patients with systemic lupus erythematosus. J Rheumatol 1999;26:1486-9.
34. Karassa FB, Trikalinos TA, Ioannidids JPA. Role of the Fcγ receptor IIA polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis. Arthritis Rheum 2002;46:1563-71.
35. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcγRIIIA (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-70.
36. Kyogoku C, Dijstelbloem HM, Tsuchiya N, Hatta Y, Kato H, Yamaguchi A, et al. Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:1242-54.
37. Köhl J, Gessner JE. On the role of complement and Fc γ-receptors in the Arthus reaction. Mol Immunol 1999;36:893-903.
38. Krause I, Blank M, Kopolovic J, Afek A, Goldberg I, Tomer Y, et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995;22:1068-74.
39. Gómez-Guerrero C, Duque N, Casado MT, Pastor C, Blanco J, Mampaso F, et al. Administration of IgG Fc fragments prevents glomerular injury in experimental immune complex nephritis. J Immunol 2000;164:2092-101.
40. Levy Y, Sherer Y, George J, Rovensky J, Lukac J, Rauova L, et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 2000;29:321-7.
41. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R. Long-term i.v. Ig treatment in systemic lupus erytbematosus. Clin Exp Rheumatol 1994;12:163-8.
42. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996;23:71-5.
43. Maier WP, Gordon DS, Howard RF, Saleh MN, Miller SB, Lieberman JD, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum 1990;33:1233-9.
44. Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, et al. Treatment of severe inamune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002;29:75-83.
45. Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross W, Kimberly RP. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via FcγRIIa. J Immunol 1994;153:1271-80.
46. Dijstelbloem HM, Scheepers RHM, Oost WW, Stegeman CA, van der Pol WL, Sluiter WJ, et al. Fcγ receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum 1999;42:1823-7.
47. Wainstein E, Edberg J, Csernok E, Sneller M, Hoffman G, Keystone E, et al. FcγRIIIB alleles predict renal dysfunction in Wegener's granulomatosis (WG). Arthritis Rheum 1996;39:S210.
48. Edberg JC, Wainstein E, Wu J, Csernok E, Sneller MC, Hoffman GS, et al. Analysis of FcγRII gene polymorphisms in Wegener's granulomatosis. Exp Clin Immunogenet 1997;14:183-95.
49. Tse WY, Abadeh S, McTiernan A, Jefferis R, Savage COS, Adu D. No association between neutrophil FcγRIIA allelic polymorpbism and anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin Exp Immunol 1999;117:198-205.
50. Tse WY, Abadeb S, Jefferis R, Savage COS, Adu D. Neutrophil FcγRIIIB allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin Exp Immunol 2000;119:574-7.
51. Richter C, Scbnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995;101:2-7.
52. Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996;35:1150-3.
53. Levy Y, Sherer Y, George J, Langevitz P, Ahmed A, Bar-Dayan Y, et al. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 1999;119:231-8.
54. Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000;93:433-9.
55. Vedeler CA, Myhr K-M, Nyland H. Fc receptors for immunoglobulin G - a role in the pathogenesis of Guillain-Barré syndrome and multiple sclerosis. J Neuroimmunol 2001;118:187-93.
56. Van der Pol W-L, van den Berg LH, Scheepers RHM, van der Bom JG, van Doorn PA, van Koningsveld R, et al. IgG receptor IIA alleles determine susceptibility and severity of Guillain-Barré syndrome. Neurology 2000;54:1661-5.
57. Vedeler CA, Raknes G, Myhr K-M, Nyland H. IgG Fc-receptor polymorphisms in Guillain-Barré syndrome. Neurology 2000;55:705-7.
58. Myhr K-M, Raknes G, Nyland H, Vedeler C. Immunoglobulin G Fc-receptor (FcγR) IIA and IIIB polymorphisms related to disability in MS. Neurology 1999;52:1771-6.
59. Buchwald B, Ahangari R, Weishaupt A. Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann Neurol 2002;51:673-80.
60. Jackson MC, Godwin-Austen RB, Whiteley AM. High-dose intravenous immunoglobulin in the treatment of Guillain-Barré syndrome: a preliminary open study. J Neurol 1993;240:51-3.
61. Gurses N, Uysal S, Cetinkaya F, Islek I, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995;27:241-3.
62. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immanoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-30.
63. Hughes RA. Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome. Ther Apher 1997;1:129-30.
64. Kuwabara S, Mori M, Ogawara K, Hattori T, Yuki N. Indicators of rapid clinical recovery in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2001;70:560-2.
65. Achiron A, Margalit R, Hershkoviz R, Markovits D, Reshef T, Melamed E, et al. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest 1994;93:600-5.
66. Bieber A, Asakura K, Warrington A, Kaveri SV, Rodriguez M. Antibody-mediated remyelination: relevance to multiple sclerosis. Mull Scler 2000;S2:S1-5.
67. Schuller E, Lambin P, Deloche G. Long-term treatment of mukiple sclerosis with IgG immunotherapy. Pathol Biol (Paris) 1996;44:710-5.
68. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997;349:589-93.
69. Achiron A, Gabbay U, Gilad R. Hassin-Baer S, Barak Y, Gornish M, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998;50:398-402.
70. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-81.
71. Francis GS, Freedman MS, Antel JP. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult Scler 1997;3:370-6.
72. Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:89-92.